BIO-1211|cas:187735-94-0|西域试剂

BIO-1211,99.64%

产品编号：Bellancom-14126| CAS NO：187735-94-0| 分子式：C₃₆H₄₈N₆O₉| 分子量：708.80

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-14126		￥2500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

BIO-1211

产品介绍

BIO-1211 是高度选择性的、具有口服活性的 α4β1 (VLA-4) 抑制剂，其对 α4β1 和 α4β7 的 IC₅₀ 值分别为 4 nM 和 2 μM。

生物活性

BIO-1211 is a highly selective and orally active α4β1 (VLA-4) inhibitor, with IC₅₀ values of 4 nM and 2 μM for α4β1 and α4β7, respectively.

体外研究

BIO-1211 almostly exhibits no activity for α1β1, α5β1, α6β1, αLβ2 and αIIbβ3.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

BIO-1211 (5 and 10 mg/kg, orally, once every other day) results in reduced cytokines expression, leukocyte trafficking, and inhibition of inflammatory responses in EAE in a dose-independent manner. BIO-1211 exhibits a considerable depletion in the EAE clinical score, which correlated with decreased expression of TNF-α, IL-17, IFN-γ and pervade of CD11b+ and CD45+ cells into the cerebral cortex.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Naive, C57BL/6 mice (male, 8 weeks old, 20-25 g weight).
Dosage:	5 and 10 mg/kg.
Administration:	Orally once every other day starting the day before immunization until day 21 post-immunization.
Result:	Could prevent the induction of EAE. Significantly delayed the onset of EAE and reduced the severity of clinical EAE compared to the vehicle group. Markedly reduced the expression of both CD11b and CD45 in comparison with the vehicle group. mRNA and soluble form of a subset of target inflammatory cytokines (IFNγ, IL-17, and TNF-α) was dramatically decreased.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Naive, C57BL/6 mice (male, 8 weeks old, 20-25 g weight).
Dosage:	5 and 10 mg/kg.
Administration:	Orally once every other day starting the day before immunization until day 21 post-immunization.
Result:	Could prevent the induction of EAE. Significantly delayed the onset of EAE and reduced the severity of clinical EAE compared to the vehicle group. Markedly reduced the expression of both CD11b and CD45 in comparison with the vehicle group. mRNA and soluble form of a subset of target inflammatory cytokines (IFNγ, IL-17, and TNF-α) was dramatically decreased.

性状

Solid

溶解性数据

In Vitro:

DMSO : 250 mg/mL (352.71 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.4108 mL	7.0542 mL	14.1084 mL
5 mM	0.2822 mL	1.4108 mL	2.8217 mL
10 mM	0.1411 mL	0.7054 mL	1.4108 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (2.93 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (2.93 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (2.93 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (2.93 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (2.93 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (2.93 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。